AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10753272 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 37
Study 8652872 — intervention group
Group type: EXPERIMENTAL
Intervention: Otoscopic exam and refit procedure
Number of subjects: 316
Study 8652872 — intervention group
Group type: COMPARATOR
Intervention: Probe refit procedure
Number of subjects: 316
Study 1422658 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Number of subjects: 61
Study 2856708 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil + propranolol
Number of subjects: 14
Study 2856708 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol
Number of subjects: 14
Study 2856708 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 14
Study 2856708 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 31982191 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-induced weight-loss program (calorie-restricted diet for six weeks)
Number of subjects: 54
Study 31982191 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-induced weight-loss program
Number of subjects: 54
Study 31982191 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained habitual diet and physical activity)
Number of subjects: 54
Study 31982191 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 30507829 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion Tub Bathing (ITB)
Number of subjects: 80
Study 30507829 — intervention group
Group type: COMPARATOR
Intervention: Underrunning Water Bathing (URWB)
Number of subjects: 80
Study 27454273 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal 10 mg of hyperbaric bupivacaine 0.5% and 5 µg of dexmedetomidine (group I)
Number of subjects: 90
Study 27454273 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal 10 mg of hyperbaric bupivacaine 0.5% and 0.1 mg/kg ketamine (group II)
Number of subjects: 90
Study 27454273 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 10 mg of hyperbaric bupivacaine 0.5%, 5 µg of dexmedetomidine, and 0.1 mg/kg of ketamine (group III)
Number of subjects: 90
Study 24149919 — intervention group
Group type: EXPERIMENTAL
Intervention: Group CBT
Number of subjects: 140
Study 24149919 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help CBT
Number of subjects: 140
Study 24149919 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 140
Study 22688651 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic gymnasts (RG)
Number of subjects: 68
Study 22688651 — intervention group
Group type: COMPARATOR
Intervention: Untrained controls (UC)
Number of subjects: 68
Study 22688651 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (RG and UC)
Number of subjects: 68
Study 20088937 — intervention group
Group type: EXPERIMENTAL
Intervention: Avidin (100 mg)
Number of subjects: 96
Study 20088937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 18397971 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Event Monitoring System (MEMS) used daily
Number of subjects: 0
Study 18397971 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Event Monitoring System (MEMS)
Number of subjects: 0
Study 16521844 — intervention group
Group type: EXPERIMENTAL
Intervention: GEL (1.1 +/- 0.2 g/kg body mass carbohydrate)
Number of subjects: 18
Study 16521844 — intervention group
Group type: COMPARATOR
Intervention: PLACEBO (flavored placebo drink, 426 +/- 227 mL)
Number of subjects: 18
Study 16521844 — intervention group
Group type: EXPERIMENTAL
Intervention: GEL
Number of subjects: 18
Study 14714551 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow band UVB
Number of subjects: 14
Study 14714551 — intervention group
Group type: COMPARATOR
Intervention: Broad band UVB
Number of subjects: 14
Study 10579151 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg orally once daily for 14 days
Number of subjects: 28
Study 10579151 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 20 mg oral dose
Number of subjects: 28
Study 10579151 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone coadministration
Number of subjects: 28
Study 8610720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (500 microgram) + metaproterenol sulfate (15 mg)
Number of subjects: 213
Study 8610720 — intervention group
Group type: COMPARATOR
Intervention: Metaproterenol sulfate (15 mg)
Number of subjects: 213
Study 8610720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide + metaproterenol sulfate
Number of subjects: 213
Study 8610720 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 213
Study 1742892 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration of middle ear effusions prior to ventilation tube insertion
Number of subjects: 50
Study 1742892 — intervention group
Group type: EXPERIMENTAL
Intervention: Ears with effusion aspirated
Number of subjects: 50
Study 6279223 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromic catgut
Number of subjects: 231
Study 6279223 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglycolic acid
Number of subjects: 231
Study 6279223 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene
Number of subjects: 231
Study 2998440 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread with 10 g bran (raw or baked) and fermentation times of 15 min, 45 min, 3 h, or 16 h
Number of subjects: 42
Study 2998440 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread with 16 g bran (raw or baked) and fermentation times of 15 min, 45 min, 3 h, or 16 h
Number of subjects: 42
Study 2998440 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread with 30 g bran (raw or baked) and fermentation times of 15 min, 45 min, 3 h, or 16 h
Number of subjects: 42
Study 2998440 — intervention group
Group type: COMPARATOR
Intervention: Bread with no bran, but phytate and Zn added equivalent to 10 g bran
Number of subjects: 42
Study 29223712 — intervention group
Group type: EXPERIMENTAL
Intervention: 2700K light exposure (55lx)
Number of subjects: 16
Study 29223712 — intervention group
Group type: COMPARATOR
Intervention: 6500K light exposure (55lx)
Number of subjects: 16
Study 29223712 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 2700K and 6500K light exposure
Number of subjects: 16
Study 26481981 — intervention group
Group type: EXPERIMENTAL
Intervention: Optic nerve sheath diameter assessment via ultrasonography
Number of subjects: 13
Study 23452436 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 312
Study 23452436 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab with last acuity of drop-outs carried forward
Number of subjects: 312
Study 23452436 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab in late phase
Number of subjects: 312
Study 23452436 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab in early phase
Number of subjects: 312
Study 22295830 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with Han's acupoint nerve stimulator (HANS) for 30 min, bilateral Zusanli (ST 36) and Sanyinjiao (SP 6)
Number of subjects: 90
Study 22295830 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with Han's acupoint nerve stimulator (HANS) for 30 min, bilateral Hegu (LI 4) and Taichong (LR 3)
Number of subjects: 90
Study 22295830 — intervention group
Group type: COMPARATOR
Intervention: Only general anesthesia
Number of subjects: 90
Study 20103782 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) - 6 mg/m² every 4 weeks for 3 cycles
Number of subjects: 232
Study 20103782 — intervention group
Group type: COMPARATOR
Intervention: Control group - no postremission therapy
Number of subjects: 232
Study 18051017 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Focused Grief Therapy
Number of subjects: 81
Study 18051017 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 81
Study 16191743 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 dopamine receptor TaqI A polymorphism
Number of subjects: 0
Study 16191743 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 11945097 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride 800 mg/day
Number of subjects: 262
Study 11945097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study 10556609 — intervention group
Group type: EXPERIMENTAL
Intervention: Attend-auditory group
Number of subjects: 0
Study 10556609 — intervention group
Group type: EXPERIMENTAL
Intervention: Attend-visual group
Number of subjects: 0
Study 8609329 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillation shocks equal to the upper limit of vulnerability (11.3 +/- 4.6 J)
Number of subjects: 40
Study 8609329 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillation shocks at upper limit of vulnerability plus 3 J (14.3 +/- 4.6 J)
Number of subjects: 40
Study 8609329 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillation test shocks at upper limit of vulnerability
Number of subjects: 40
Study 1888345 — intervention group
Group type: COMPARATOR
Intervention: Triazolam
Number of subjects: 30
Study 1888345 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment (stimulus control/relaxation training)
Number of subjects: 30
Study 6405771 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 0
Study 6405771 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine
Number of subjects: 0
Study 6405771 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 0
Study 6405771 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate
Number of subjects: 0
Study 31412032 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anaesthesia
Number of subjects: 0
Study 31412032 — intervention group
Group type: COMPARATOR
Intervention: Injectable anaesthesia
Number of subjects: 0
Study 30400939 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly high-dose recombinant human erythropoietin (EPO) 40,000 IU/mL for 12 weeks
Number of subjects: 104
Study 30400939 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) infusions for 12 weeks
Number of subjects: 104
Study 26790543 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive self-ligating brackets
Number of subjects: 100
Study 26790543 — intervention group
Group type: EXPERIMENTAL
Intervention: Active self-ligating brackets
Number of subjects: 100
Study 26790543 — intervention group
Group type: EXPERIMENTAL
Intervention: Total space closure
Number of subjects: 100
Study 26790543 — intervention group
Group type: COMPARATOR
Intervention: Conventional brackets
Number of subjects: 100
Study 24715364 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine plasma levels (Clz pl≥300μg/L)
Number of subjects: 19
Study 24715364 — intervention group
Group type: COMPARATOR
Intervention: Clozapine plasma levels (Clz pl<300μg/L)
Number of subjects: 19
Study 24715364 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine plasma levels
Number of subjects: 19
Study 22713233 — intervention group
Group type: EXPERIMENTAL
Intervention: Bodyblade Pro
Number of subjects: 11
Study 22713233 — intervention group
Group type: COMPARATOR
Intervention: 10-lb dumbbell
Number of subjects: 11
Study 20843911 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60‐120 mg/day
Number of subjects: 530
Study 20843911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study 17585670 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming needle moxibustion plus acupuncture at Shenshu (BIL 23), Mingmen (GV 4), Yaoyangguan (GV 3), and Weizhong (BL 40)
Number of subjects: 78
Study 17585670 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at Shenshu (BIL 23), Mingmen (GV 4), Yaoyangguan (GV 3), and Weizhong (BL 40)
Number of subjects: 78
Study 17585670 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming needle moxibustion plus acupuncture
Number of subjects: 78
Study 17585670 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 78
Study 15793941 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal seven-valent conjugate vaccine (Prevenar)
Number of subjects: 115
Study 12400812 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct primary stenting (group 1, n = 50)
Number of subjects: 100
Study 12400812 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic atraumatic coronary artery bypass grafting (group 2, n = 50)
Number of subjects: 100
Study 11607795 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg or Enalapril 20 mg (for patients ≤40 years); Amlodipine 10 mg + Atenolol 50 mg or Enalapril 20 mg + Hydrochlorothiazide 25 mg (for patients >40 years)
Number of subjects: 1106
Study 11607795 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor treatment
Number of subjects: 1106
Study 11607795 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine-based regimen
Number of subjects: 1106
Study 11607795 — intervention group
Group type: COMPARATOR
Intervention: Enalapril-based regimen
Number of subjects: 1106
Study 9893735 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg twice a day
Number of subjects: 10
Study 9893735 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 60 mg/day
Number of subjects: 10
Study 9893735 — intervention group
Group type: COMPARATOR
Intervention: L-NMMA (0.75, 1.5, and 3.0 mg/kg/h)
Number of subjects: 10
Study 8281874 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 150 mg four times a day
Number of subjects: 23
Study 8281874 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 23
Study 2604918 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% carbon monoxide exposure
Number of subjects: 63
Study 2604918 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% carbon monoxide exposure
Number of subjects: 63
Study 2604918 — intervention group
Group type: COMPARATOR
Intervention: Control (air without added carbon monoxide)
Number of subjects: 63
Study 1089439 — intervention group
Group type: EXPERIMENTAL
Intervention: Fegan's method
Number of subjects: 0
Study 1089439 — intervention group
Group type: COMPARATOR
Intervention: Operation
Number of subjects: 0
Study 7223302 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin therapy (60-75 g postoperatively)
Number of subjects: 59
Study 7223302 — intervention group
Group type: COMPARATOR
Intervention: Control (no albumin)
Number of subjects: 59
Study 7223302 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin therapy
Number of subjects: 59
Study 7223302 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 59
Study 7223302 — intervention group
Group type: COMPARATOR
Intervention: Albumin therapy and Control
Number of subjects: 59
Study 31647931 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional trials
Number of subjects: 390
Study 30185291 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist intervention (e.g., medication dose adjustment, initiation, or discontinuation)
Number of subjects: 2594
Study 30185291 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors predictive of requiring an intervention (e.g., clopidogrel dispensing, fall, vertebral fracture diagnosis)
Number of subjects: 2594
Study 30185291 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation of the predictive model
Number of subjects: 2594
Study 27038924 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol
Number of subjects: 110
Study 27038924 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ibuprofen
Number of subjects: 110
Study 24355669 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention
Number of subjects: 44
Study 24355669 — intervention group
Group type: EXPERIMENTAL
Intervention: Workstations-only intervention
Number of subjects: 44
Study 24355669 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (usual practice)
Number of subjects: 44
Study 22313514 — intervention group
Group type: EXPERIMENTAL
Intervention: Remi-Pro-Rocu group (n = 62)
Number of subjects: 126
Study 22313514 — intervention group
Group type: COMPARATOR
Intervention: Pro-Rocu-Remi group (n = 64)
Number of subjects: 126
Study 20602433 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based group CBT
Number of subjects: 148
Study 20602433 — intervention group
Group type: COMPARATOR
Intervention: Structured after-school activity group
Number of subjects: 148
Study 17660026 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF), 1 g twice daily for 12 months
Number of subjects: 64
Study 17660026 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, 1.5 mg/kg/d for 12 months
Number of subjects: 64
Study 16043178 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 80
Study 16043178 — intervention group
Group type: COMPARATOR
Intervention: Nifedipin
Number of subjects: 80
Study 11799102 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 40 mg/d
Number of subjects: 18
Study 11799102 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 80 mg/d
Number of subjects: 18
Study 11799102 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 160 mg/d
Number of subjects: 18
Study 11799102 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 20 mg/d
Number of subjects: 18
Study 11799102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10320183 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine/prilocaine cream (EMLA; Astra, Sweden) for 1 hour postburn
Number of subjects: 10
Study 10320183 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream for 1 hour postburn
Number of subjects: 10
Study 8542174 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy for colorectal cancer
Number of subjects: 0
Study 1961137 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg midazolam HCl
Number of subjects: 23
Study 1961137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 7144067 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 16
Study 7144067 — intervention group
Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 16
Study 31958286 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line EGFR inhibitors
Number of subjects: 0
Study 31958286 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31073879 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-Based Cognitive Behavioral Therapy (CBT), 12 sessions
Number of subjects: 71
Study 31073879 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 71
Study 30096070 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC (tenofovir/emtricitabine)
Number of subjects: 31
Study 30096070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 27101402 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-3L
Number of subjects: 71
Study 27101402 — intervention group
Group type: EXPERIMENTAL
Intervention: ICECAP-O
Number of subjects: 71
Study 23640540 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI
Number of subjects: 108
Study 23640540 — intervention group
Group type: EXPERIMENTAL
Intervention: no diagnosis
Number of subjects: 108
Study 23640540 — intervention group
Group type: COMPARATOR
Intervention: concussion
Number of subjects: 108
Study 22231680 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for general practitioners, including training and consultations for patients.
Number of subjects: 490
Study 22231680 — intervention group
Group type: COMPARATOR
Intervention: Usual care by general practitioners (control group).
Number of subjects: 490
Study 20573086 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea
Number of subjects: 12
Study 20573086 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol
Number of subjects: 12
Study 17535463 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial strategy during free-choice phase
Number of subjects: 0
Study 17535463 — intervention group
Group type: COMPARATOR
Intervention: Incentive to perform as well as possible
Number of subjects: 0
Study 17535463 — intervention group
Group type: COMPARATOR
Intervention: Difficulty executing the better alternative (cancellation)
Number of subjects: 0
Study 17535463 — intervention group
Group type: COMPARATOR
Intervention: Prone to making errors at the spatial strategy
Number of subjects: 0
Study 16266457 — intervention group
Group type: COMPARATOR
Intervention: 500 micromol/L Hcy
Number of subjects: 101
Study 16266457 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid with 500 micromol/L Hcy
Number of subjects: 101
Study 16266457 — intervention group
Group type: COMPARATOR
Intervention: Hcy in AMI group
Number of subjects: 101
Study 12202284 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl-eicosapentaenoic acid (E-EPA)
Number of subjects: 40
Study 12202284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10428146 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg once daily for 12 months
Number of subjects: 46
Study 10428146 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 250 mg twice daily for 12 months
Number of subjects: 46
Study 7785475 — intervention group
Group type: EXPERIMENTAL
Intervention: Women in their first year on campus
Number of subjects: 0
Study 7785475 — intervention group
Group type: EXPERIMENTAL
Intervention: Both women and men
Number of subjects: 0
Study 7785475 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 0
Study 2097149 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP (C = 600 mg/sqm, A = 45 mg/sqm, P = 50 mg/sqm)
Number of subjects: 134
Study 2097149 — intervention group
Group type: COMPARATOR
Intervention: CA (C = 600 mg/sqm, A = 45 mg/sqm)
Number of subjects: 134
Study 2097149 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP
Number of subjects: 134
Study 2097149 — intervention group
Group type: COMPARATOR
Intervention: CA
Number of subjects: 134
Study 381127 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 42
Study 381127 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 42
Study 381127 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine group
Number of subjects: 42
Study 381127 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 42